MD3788044T2 - Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora - Google Patents
Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestoraInfo
- Publication number
- MD3788044T2 MD3788044T2 MDE20210212T MDE20210212T MD3788044T2 MD 3788044 T2 MD3788044 T2 MD 3788044T2 MD E20210212 T MDE20210212 T MD E20210212T MD E20210212 T MDE20210212 T MD E20210212T MD 3788044 T2 MD3788044 T2 MD 3788044T2
- Authority
- MD
- Moldova
- Prior art keywords
- inhibitory compounds
- rip1
- making
- methods
- same
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 230000002401 inhibitory effect Effects 0.000 title abstract 4
- 101000643956 Homo sapiens Cytochrome b-c1 complex subunit Rieske, mitochondrial Proteins 0.000 title abstract 3
- 101001099199 Homo sapiens RalA-binding protein 1 Proteins 0.000 title abstract 3
- 101001109145 Homo sapiens Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 title abstract 3
- 102100021009 Cytochrome b-c1 complex subunit Rieske, mitochondrial Human genes 0.000 title 1
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Abstract
Prezenta invenţie se referă la compuşi inhibitori de kinază, cum ar fi compuşii inhibitori de kinază, care interacţionează cu receptorul proteinei -1 (RIP1), precum şi la compoziţii şi combinaţii farmaceutice, care conţin astfel de compuşi inhibitori.Compuşii, compoziţiile şi/sau combinaţiile farmaceutice , conform invenţiei, pot fi utilizate pentru a trata sau a preveni o boală sau o stare asociată cu o kinază, în particular o boală sau o stare asociată cu RIP1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666462P | 2018-05-03 | 2018-05-03 | |
| PCT/US2019/030476 WO2019213447A1 (en) | 2018-05-03 | 2019-05-02 | Rip1 inhibitory compounds and methods for making and using the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MD3788044T2 true MD3788044T2 (ro) | 2023-12-31 |
Family
ID=66530556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MDE20210212T MD3788044T2 (ro) | 2018-05-03 | 2019-05-02 | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
Country Status (34)
| Country | Link |
|---|---|
| US (7) | US10815206B2 (ro) |
| EP (2) | EP4248975A3 (ro) |
| JP (4) | JP2021523226A (ro) |
| KR (1) | KR20210005222A (ro) |
| CN (1) | CN112368278A (ro) |
| AU (2) | AU2019262144B2 (ro) |
| BR (1) | BR112020022420A2 (ro) |
| CA (1) | CA3099037A1 (ro) |
| CL (1) | CL2020002841A1 (ro) |
| CO (1) | CO2020015156A2 (ro) |
| CR (1) | CR20200581A (ro) |
| DK (1) | DK3788044T3 (ro) |
| DO (2) | DOP2020000198A (ro) |
| EA (1) | EA202092580A1 (ro) |
| EC (1) | ECSP20078326A (ro) |
| ES (1) | ES2956087T3 (ro) |
| FI (1) | FI3788044T3 (ro) |
| HR (1) | HRP20231381T1 (ro) |
| HU (1) | HUE063896T2 (ro) |
| IL (2) | IL299784B2 (ro) |
| JO (1) | JOP20200278A1 (ro) |
| LT (1) | LT3788044T (ro) |
| MA (1) | MA52488B1 (ro) |
| MD (1) | MD3788044T2 (ro) |
| MX (1) | MX2020011621A (ro) |
| PE (1) | PE20211383A1 (ro) |
| PH (1) | PH12020551847A1 (ro) |
| PL (1) | PL3788044T3 (ro) |
| PT (1) | PT3788044T (ro) |
| RS (1) | RS64736B1 (ro) |
| SG (1) | SG11202010915XA (ro) |
| SI (1) | SI3788044T1 (ro) |
| WO (1) | WO2019213447A1 (ro) |
| ZA (2) | ZA202007486B (ro) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MD3788044T2 (ro) * | 2018-05-03 | 2023-12-31 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| AU2019262142A1 (en) | 2018-05-03 | 2020-11-26 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| JP7045526B2 (ja) * | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| CN111138448B (zh) * | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| CR20220075A (es) * | 2019-09-06 | 2022-07-14 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos |
| US11718612B2 (en) | 2019-09-06 | 2023-08-08 | Board Of Regents, The University Of Texas System | Inhibitors of receptor interacting protein kinase I for the treatment of disease |
| JP7443495B2 (ja) | 2019-09-06 | 2024-03-05 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ヘテロ環式ｒｉｐ１キナーゼ阻害剤 |
| MX2022003671A (es) | 2019-09-27 | 2022-04-25 | Univ Texas | Inhibidores de proteina cinasa i de interaccion con receptores para el tratamiento de enfermedades. |
| CN113015974A (zh) * | 2019-10-21 | 2021-06-22 | 谷歌有限责任公司 | 针对隐私保护的可验证同意 |
| MX2022005509A (es) | 2019-11-07 | 2022-10-18 | Rigel Pharmaceuticals Inc | Compuestos inhibidores de rip1 heterociclicos. |
| JP2023502514A (ja) * | 2019-11-26 | 2023-01-24 | ボード オブ レジェンツ，ザ ユニバーシティ オブ テキサス システム | 疾患の処置のための受容体相互作用プロテインキナーゼｉの阻害剤 |
| EP4110765A4 (en) * | 2020-02-28 | 2024-03-06 | Univ Texas | INHIBITORS OF RECEPTOR INTERACTING PROTEIN KINASE I FOR THE TREATMENT OF DISEASES |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| WO2022171111A1 (en) * | 2021-02-10 | 2022-08-18 | Zai Lab (Us) Llc | Heteroaryl-fused bicyclic compound as rip1-kinase inhibitors and uses thereof |
| CN114989156A (zh) * | 2021-05-19 | 2022-09-02 | 成都贝诺科成生物科技有限公司 | 一种受体相互作用蛋白抑制剂及其制备方法和用途 |
| JP7406672B2 (ja) | 2021-08-10 | 2023-12-27 | アッヴィ・インコーポレイテッド | ニコチンアミド系ｒｉｐｋ１阻害剤 |
| WO2023114061A1 (en) | 2021-12-16 | 2023-06-22 | Rigel Pharmaceuticals, Inc. | Crystalline forms of a ripk1 inhibitor |
| CN116478150A (zh) * | 2022-01-21 | 2023-07-25 | 中国科学院上海药物研究所 | 具有ripk1抑制活性的化合物、其制备方法及其用途 |
| CN114736197B (zh) * | 2022-06-13 | 2022-09-13 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
| CN115353513A (zh) * | 2022-07-29 | 2022-11-18 | 中国人民解放军海军军医大学 | 一种抑制程序性细胞坏死的硫代七元环衍生物及其应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4921475A (en) | 1983-08-18 | 1990-05-01 | Drug Delivery Systems Inc. | Transdermal drug patch with microtubes |
| US5087240A (en) | 1983-08-18 | 1992-02-11 | Drug Delivery Systems Inc. | Transdermal drug patch with conductive fibers |
| US4738851A (en) | 1985-09-27 | 1988-04-19 | University Of Iowa Research Foundation, Inc. | Controlled release ophthalmic gel formulation |
| US5163899A (en) | 1987-03-20 | 1992-11-17 | Drug Delivery Systems Inc. | Transdermal drug delivery system |
| US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
| GB8804164D0 (en) | 1988-02-23 | 1988-03-23 | Tucker J M | Bandage for administering physiologically active compound |
| US4882150A (en) | 1988-06-03 | 1989-11-21 | Kaufman Herbert E | Drug delivery system |
| US5008110A (en) | 1988-11-10 | 1991-04-16 | The Procter & Gamble Company | Storage-stable transdermal patch |
| US5088977A (en) | 1988-12-21 | 1992-02-18 | Drug Delivery Systems Inc. | Electrical transdermal drug applicator with counteractor and method of drug delivery |
| US5521222A (en) | 1989-09-28 | 1996-05-28 | Alcon Laboratories, Inc. | Topical ophthalmic pharmaceutical vehicles |
| CA2031376A1 (en) | 1989-12-04 | 1991-06-05 | Bahram Farhadieh | Single layer transdermal drug administration system |
| US5077033A (en) | 1990-08-07 | 1991-12-31 | Mediventures Inc. | Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide |
| JP2594486B2 (ja) | 1991-01-15 | 1997-03-26 | アルコン ラボラトリーズ インコーポレイテッド | 局所的眼薬組成物 |
| US5352456A (en) | 1991-10-10 | 1994-10-04 | Cygnus Therapeutic Systems | Device for administering drug transdermally which provides an initial pulse of drug |
| JPH07502219A (ja) | 1991-12-18 | 1995-03-09 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | 多重層型バリアー構造体 |
| EP0553769B1 (de) | 1992-01-29 | 1996-01-03 | FRANZ VÖLKL GmbH & CO. SKI UND TENNIS SPORTARTIKELFABRIK KG | Ballspielschläger, insbesondere Tennisschläger |
| IL114193A (en) | 1994-06-20 | 2000-02-29 | Teva Pharma | Ophthalmic pharmaceutical compositions based on sodium alginate |
| ES2094688B1 (es) | 1994-08-08 | 1997-08-01 | Cusi Lab | Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion. |
| IT1283911B1 (it) | 1996-02-05 | 1998-05-07 | Farmigea Spa | Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo |
| US5800807A (en) | 1997-01-29 | 1998-09-01 | Bausch & Lomb Incorporated | Ophthalmic compositions including glycerin and propylene glycol |
| US6261547B1 (en) | 1998-04-07 | 2001-07-17 | Alcon Manufacturing, Ltd. | Gelling ophthalmic compositions containing xanthan gum |
| US6197934B1 (en) | 1998-05-22 | 2001-03-06 | Collagenesis, Inc. | Compound delivery using rapidly dissolving collagen film |
| US20090099242A1 (en) | 2007-08-15 | 2009-04-16 | Cuny Gregory D | Heterocyclic inhibitors of necroptosis |
| TWI637951B (zh) * | 2013-02-15 | 2018-10-11 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 |
| EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
| CN106573006A (zh) * | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| JP2018505199A (ja) | 2015-02-13 | 2018-02-22 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | （Ｓ）−５−ベンジル−Ｎ−（５−メチル−４−オキソ−２，３，４，５テトラヒドロベンゾ［ｂ］［１，４］オキサゼピン−３−イル）−４Ｈ−１，２，４−トリアゾール−３−カルボキサミドの結晶形 |
| TWI763630B (zh) * | 2015-07-02 | 2022-05-11 | 瑞士商赫孚孟拉羅股份公司 | 雙環內醯胺及其使用方法 |
| WO2017064217A1 (en) | 2015-10-13 | 2017-04-20 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Sibiriline derivatives for use for preventing and/or treating disorders associated with cellular necroptosis |
| US10787462B2 (en) | 2015-10-23 | 2020-09-29 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| MY196648A (en) | 2016-02-05 | 2023-04-27 | Denali Therapeutics Inc | Inhibitors of Receptor-Interacting Protein Kinase 1 |
| EP3526219B1 (en) * | 2016-10-17 | 2021-12-15 | F. Hoffmann-La Roche AG | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| US20200062735A1 (en) * | 2017-02-27 | 2020-02-27 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| AU2019262142A1 (en) | 2018-05-03 | 2020-11-26 | Rigel Pharmaceuticals, Inc. | RIP1 inhibitory compounds and methods for making and using the same |
| MD3788044T2 (ro) | 2018-05-03 | 2023-12-31 | Rigel Pharmaceuticals Inc | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora |
| US20210292340A1 (en) | 2018-06-26 | 2021-09-23 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Cell necrosis inhibitor, preparation method therefor and use thereof |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| JP7443495B2 (ja) | 2019-09-06 | 2024-03-05 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ヘテロ環式ｒｉｐ１キナーゼ阻害剤 |
-
2019
- 2019-05-02 MD MDE20210212T patent/MD3788044T2/ro unknown
- 2019-05-02 HU HUE19724048A patent/HUE063896T2/hu unknown
- 2019-05-02 JO JOP/2020/0278A patent/JOP20200278A1/ar unknown
- 2019-05-02 RS RS20230982A patent/RS64736B1/sr unknown
- 2019-05-02 IL IL299784A patent/IL299784B2/en unknown
- 2019-05-02 EP EP23181764.4A patent/EP4248975A3/en active Pending
- 2019-05-02 EP EP19724048.4A patent/EP3788044B1/en active Active
- 2019-05-02 CN CN201980045101.1A patent/CN112368278A/zh active Pending
- 2019-05-02 SG SG11202010915XA patent/SG11202010915XA/en unknown
- 2019-05-02 DK DK19724048.4T patent/DK3788044T3/da active
- 2019-05-02 HR HRP20231381TT patent/HRP20231381T1/hr unknown
- 2019-05-02 FI FIEP19724048.4T patent/FI3788044T3/fi active
- 2019-05-02 CA CA3099037A patent/CA3099037A1/en active Pending
- 2019-05-02 US US16/402,111 patent/US10815206B2/en active Active
- 2019-05-02 JP JP2021510284A patent/JP2021523226A/ja not_active Withdrawn
- 2019-05-02 PT PT197240484T patent/PT3788044T/pt unknown
- 2019-05-02 AU AU2019262144A patent/AU2019262144B2/en active Active
- 2019-05-02 WO PCT/US2019/030476 patent/WO2019213447A1/en active Application Filing
- 2019-05-02 PE PE2020001784A patent/PE20211383A1/es unknown
- 2019-05-02 IL IL278417A patent/IL278417B1/en unknown
- 2019-05-02 ES ES19724048T patent/ES2956087T3/es active Active
- 2019-05-02 PL PL19724048.4T patent/PL3788044T3/pl unknown
- 2019-05-02 MA MA52488A patent/MA52488B1/fr unknown
- 2019-05-02 MX MX2020011621A patent/MX2020011621A/es unknown
- 2019-05-02 KR KR1020207034549A patent/KR20210005222A/ko unknown
- 2019-05-02 EA EA202092580A patent/EA202092580A1/ru unknown
- 2019-05-02 CR CR20200581A patent/CR20200581A/es unknown
- 2019-05-02 BR BR112020022420-0A patent/BR112020022420A2/pt active Search and Examination
- 2019-05-02 LT LTEPPCT/US2019/030476T patent/LT3788044T/lt unknown
- 2019-05-02 SI SI201930598T patent/SI3788044T1/sl unknown
-
2020
- 2020-09-16 US US17/023,149 patent/US11370765B2/en active Active
- 2020-09-16 US US17/023,136 patent/US11370764B2/en active Active
- 2020-09-16 US US17/023,138 patent/US11377428B2/en active Active
- 2020-09-16 US US17/023,127 patent/US11332451B2/en active Active
- 2020-10-16 US US17/072,862 patent/US11472782B2/en active Active
- 2020-11-02 CL CL2020002841A patent/CL2020002841A1/es unknown
- 2020-11-02 DO DO2020000198A patent/DOP2020000198A/es unknown
- 2020-11-03 PH PH12020551847A patent/PH12020551847A1/en unknown
- 2020-12-01 ZA ZA2020/07486A patent/ZA202007486B/en unknown
- 2020-12-01 CO CONC2020/0015156A patent/CO2020015156A2/es unknown
- 2020-12-03 EC ECSENADI202078326A patent/ECSP20078326A/es unknown
-
2021
- 2021-11-04 ZA ZA2021/08603A patent/ZA202108603B/en unknown
-
2022
- 2022-08-10 JP JP2022128202A patent/JP7187729B2/ja active Active
- 2022-09-07 US US17/939,020 patent/US20230113841A1/en active Pending
- 2022-11-30 JP JP2022191875A patent/JP7367169B2/ja active Active
-
2023
- 2023-08-25 DO DO2023000169A patent/DOP2023000169A/es unknown
- 2023-10-11 JP JP2023175695A patent/JP2024009916A/ja active Pending
- 2023-10-26 AU AU2023254980A patent/AU2023254980A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MD3788044T2 (ro) | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora | |
| MD3788045T2 (ro) | Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora | |
| MX2022002737A (es) | Compuestos inhibidores de rip1 y metodos para hacer y utilizar los mismos. | |
| MD3472167T2 (ro) | Compuși heterociclici ca imunomodulatori | |
| MD3394033T2 (ro) | Compuși heterociclici ca imunomodulatori | |
| MD3433234T2 (ro) | Modulatori alosterici ai receptorilor nicotinici de acetilcolină | |
| MD3371190T2 (ro) | Compuși heterociclici ca inhibitori PI3K-gamma | |
| MD3519398T2 (ro) | Compus de piridină | |
| SG10201908839QA (en) | 2,4-dihydroxy-nicotinamides as apj agonists | |
| CR20220075A (es) | Compuestos inhibidores de rip1 y métodos para prepararlos y usarlos | |
| MX2022011695A (es) | Compuestos para dispositivos opticamente activos. | |
| MX2019009606A (es) | Bis-compuestos para dispositivos opticamente activos. | |
| BR112019005329A2 (pt) | composições de oligossacarídeos de leite humano purificadas | |
| MD3303331T2 (ro) | Modulatori alosterici pozitivi ai receptorilor muscarinici M1 | |
| MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
| MX2020002123A (es) | Sales de ribociclib y formas en estado sólido de las mismas. | |
| MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
| MX2022001764A (es) | Composiciones que comprenden tigolaner para el control de parasitos. | |
| TN2015000542A1 (en) | Novel compounds for the treatment of cancer | |
| MD3233862T2 (ro) | Derivați ai imidazopiridazinei în calitate de inhibitori ai pΙ3Κbeta | |
| BRPI0511908A (pt) | derivados de aza-biciclo[3.1.0]hex-1-il ativos como antagonistas de nk1 | |
| WO2017106798A3 (en) | Compositions and methods for treating gluten intolerance and disorders arising therefrom | |
| WO2018204830A3 (en) | INHIBITION OF SENESCENT PROCESSES IN BETA CELLS FOR THE PREVENTION OF TYPE 1 DIABETES | |
| WO2020065090A3 (en) | 5-ht7 antagonist for the treatment of dementia-associated tauopathies | |
| BR112022001847A2 (pt) | Uso de antagonistas multiméricos de e-selectina altamente potentes para tratamento da doença de células falciformes |